Abcam and BrickBio Announce a Partnership to Incorporate Conjugation-Ready Sites into Recombinant Antibodies Across Abcam’s Portfolio

BrickBio’s technology enables efficient placement of unnatural amino acids into recombinant antibodies at specific sites Together, the organizations will industrialize the technology to serve both the research and diagnostic markets CAMBRIDGE, UK and BOSTON, MA, USA, November 08, 2019 / B3C newswire / — Abcam plc, a global innovator in life science reagents and tools, is today pleased... Read more

GE Healthcare opens lab for life science start-ups at Alderley Park, United Kingdom

NOVEMBER 06, 2019 By GE Healthcare Life Sciences • Lab will support acceleration of biotechnology, health and life sciences research in the UK• Companies to gain access to fully-equipped lab with the latest GE Healthcare Life Sciences technologies GE Healthcare Life Sciences will inaugurate an open-access lab at Alderley Park’s Mereside Campus, the UK’s largest single-site life sciences... Read more

QIAGEN expands portfolio of immuno-oncology assets for future companion diagnostics and biomarkers

Collaborates with Repertoire Genesis for access to T-cell /B-cell receptor repertoire assays for clinical next-generation sequencing Acquires licensing rights for epigenomic (DNA methylation) immune checkpoint inhibitor biomarkers developed by researchers from the University of Bonn Receives exclusive license to novel mRNA gene expression signatures from STRATIFYER Molecular Pathology GmbH which may guide treatment decisions for... Read more

PerkinElmer Genomics’ Clinical Labs in U.S. and Malaysia to Process Samples with Vanadis Fully Automated NIPT Platform

Technology Provides Pregnant Women Widespread NIPT Access WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 29, 2019– PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that PerkinElmer Genomics will begin processing samples with the Vanadis® fully automated non-invasive prenatal testing (NIPT) system at its state-of-the-art CLIA and CAP-certified clinical laboratory in Pittsburgh,... Read more

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 29 October 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more

Bruker Launches Ultrafast FTIR Imaging Microscope LUMOS II

ETTLINGEN, Germany, October 28, 2019 – Bruker today announced the launch of the novel, stand-alone FTIR (Fourier Transform Infrared) imaging microscope LUMOS II, which provides ultrafast FTIR imaging capabilities using focal-plane array (FPA) detectors in its high-end version. The new, automated LUMOS II is designed to identify particles, to determine coatings and contaminations, and to... Read more

Thermo Fisher Scientific Launches New External Molecular Control Panel for the Analytical Evaluation of BCR-ABL Test Methods

Thermo Fisher Scientific Launches New External Molecular Control Panel for the Analytical Evaluation of BCR-ABL Test Methods FREMONT, Calif., Oct. 17, 2019 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its latest molecular quality control panel. The Acrometrix BCR-ABL Panel is... Read more

GE Healthcare and Premier Inc. to Develop Model for One-Stop Breast Cancer Diagnostic Center to Give Women in the United States Same-Day Results

CHICAGO, IL and CHARLOTTE, N.C. (October 16, 2019) – GE Healthcare and Premier Inc. (NASDAQ: PINC) announced a collaboration to develop a model to bring a same-day breast cancer diagnosis and treatment model to the United States. A similar model has already proven effective at the Gustave Roussy Cancer Campus in France. Launched in 2004,... Read more

BD and Check-Points Receive FDA Clearance for Molecular Screening Test to Detect Antibiotic-Resistant Bacteria

Oct 29, 2019 FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that FDA 510(k) clearance was obtained for a molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System. The BD MAX™ Check-Points... Read more